Revenio Group Corporation has published its annual reporting package for 2024. The annual reporting package comprises of the Report by the Board of Directors, Financial Statements and Auditor’s Report, the Sustainability Report, the Corporate Governance Statement, and the Remuneration Report. The reports are available in both Finnish and English.

The reports are attached to this release and are also available on the company’s website at www.reveniogroup.fi/en/investors/reports_and_presentations.

Revenio’s Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements are published in Finnish and English. In line with the ESEF requirements, the consolidated financial statements’ primary statements, notes, and company identification information have been labeled with iXBRL tags. The audit firm Deloitte Oy has provided an independent auditor's assurance report on Revenio's Finnish-language ESEF financial statements based on a reasonable assurance engagement performed in accordance with the ISAE 3000 assurance standard.

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Ltd
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.